Anti-KIR: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 25 relapsed or refractory MM patients showed that 0.0003-3 mg/kg IPH 2101 was well tolerated. There was 1 grade 4 adverse event of acute renal fai...